The European Commission has granted marketing authorization to MabCampath® (alemtuzumab) for the treatment of patients with B-cell chronic lymphocytic leukemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments